Loading…
← CockpitCompetitor Analysis › 000756.SZ Shandong Xinhua Pharmaceutical Company Limited Class AOpen in the cockpit ↗

Shandong Xinhua Pharmaceutical Company Limited Class A000756.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

Shandong state-owned API maker and one of the world's largest producers of caffeine and analgesic bulk drugs.

≈ A Chinese state-owned bulk-analgesic/caffeine API makerMomentum strong 61
Mkt cap
$1.01B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$17.7M
20-day average traded
Fwd P/E
20.0×
forward earnings
ROIC−WACC
+1.4 pp
WACC 7.4%
Hurdle
-7 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥11.90
1D-1.1%
1W-5.4%
1M-9.3%
3M-15.2%
6M-16.7%
YTD-22.8%
1Y-25.2%
ATR %3.0%
52w lowhigh36.4% off high

What Shandong Xinhua Pharmaceutical does

Shandong state-owned API maker and one of the world's largest producers of caffeine and analgesic bulk drugs.

Makes active drug ingredients in bulk and sells them to drug formulators and, in the case of caffeine, to food and drink makers, so earnings follow the price of each compound rather than brand strength. Finished generic drugs, sold through hospitals and pharmacies in China, are a separate line.

In one line: A Chinese state-owned bulk-analgesic/caffeine API maker.

Products and services

  • Caffeine API
  • Analgesic APIs (e.g. aminopyrine)
  • Finished generic formulations

Customers

  • Generic-drug formulators worldwide
  • Beverage/food companies (caffeine)

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Analgesic and caffeine APIs

What could go right

  • Global bulk-API export demand

What could go wrong

  • Commodity price competition
  • Environmental compliance costs

Moat: narrow (scale). Large-scale bulk API production gives cost advantages in commodity analgesic and caffeine markets.

Headquarters: Zibo, Shandong, China · Employees: 7,240

Named competitors

Shandong Xinhua Pharmaceutical at a glance

Size Shandong Xinhua Pharmaceutical (000756.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.01B, the 2136th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.90 on 18 Nov 2026.

Performance Over six months the shares fell 16.7%, against -14.4% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 5.2% over the last twelve months (peer median +7.2%); the operating margin is 3.6% (peer median 16.6%).

Valuation It trades at 20.0× forward earnings against a peer median of 18.4× (9th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.4 points above its cost of capital (7.4% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 87000756.SZ 83
Six months, rebased to 100: Shandong Xinhua Pharmaceutical against the median of its 20 peers (local-currency closes).

Shandong Xinhua Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.05BCN¥8.73BCN¥8.47BCN¥8.01BCN¥7.44B
Revenue growth—+3%+6%+8%—
Gross profitCN¥1.82BCN¥1.45BCN¥1.90BCN¥2.21BCN¥1.88B
EBITDAn/aCN¥950MCN¥1.06BCN¥1.03BCN¥958M
Net incomeCN¥229MCN¥290MCN¥470MCN¥497MCN¥411M
Free cash flowCN¥319MCN¥428MCN¥163M-CN¥51.7MCN¥521M
Capital expenditureCN¥82.8MCN¥116MCN¥212MCN¥325MCN¥245M
Total debtCN¥1.76BCN¥2.03BCN¥2.14BCN¥1.87BCN¥1.89B

Quarterly statements and history in the cockpit →

Shandong Xinhua Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%APN002275002219PHN2142CRON0460PHM603262BIOG-B6472JWEL2877300791600488SUDEEPPHRM300039600216002562000756.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Xinhua Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×APN002275002219PHN2142CRON0460PHM603262BIOG-B6472JWEL2877300791SUDEEPPHRM000756.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Xinhua Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%APN002275PHN2142CRONPHM603262BIOG-B6472JWEL300791600488300039600216002562000756.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Xinhua Pharmaceutical is the large dot.

Shandong Xinhua Pharmaceutical competitors and peer comparison

Head to head with its named competitors (000756.SZ vs 600812.SS vs 000597.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shandong Xinhua Pharmaceutical 000756.SZ$1.01B-17%-5%4%20.0×0.5%
North China Pharmaceutical 600812.SS$1.08B-12%-21%5%n/a1.0%
Northeast Pharmaceutical 000597.SZ$895M-14%-6%3%n/a-7.6%

How Shandong Xinhua Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Xinhua Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000756.SZPeer medianRank in peer set
1-month return-9.3%-3.7%8th lowest of 21
6-month return-16.7%-14.4%11th highest of 21
Distance from 52-week high-36.4%-36.2%11th highest of 21
Revenue growth (TTM)-5.2%+7.2%8th lowest of 21
Operating margin3.6%16.6%3rd lowest of 21
Forward P/E20.0×18.4×9th cheapest of 17
Growth the price implies (Req g, 7 yrs)0.5%4.4%5th least demanding of 17
Growth delivered (Del g)+7.9%+14.4%6th lowest of 17
Hurdle (Req g minus delivered)-7.3 pp-10.6 pp7th most demanding of 17
ROIC minus cost of capital+1.4 pp+2.7 pp9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%

Questions

Who are Shandong Xinhua Pharmaceutical's main competitors?
Named competitors: North China Pharmaceutical (600812.SS), Northeast Pharmaceutical Group (000597.SZ). The cockpit's measured peer set (industry) also includes Applied Nutrition (APN.L), Guilin Sanjin Pharmaceutical (002275.SZ), New Journey Health Technology Group Co., Ltd.Class A (002219.SZ), PharmaNutra (PHN.MI), HBM (2142.HK), Cronos (CRON.TO).
Is Shandong Xinhua Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 20.0× against a peer median of 18.4×, 9th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Shandong Xinhua Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -16.7% against -14.4% for the median peer; over one year -25.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.